跳至主要内容
临床试验/NCT03930628
NCT03930628进行中(未招募)不适用

Limb-Girdle Muscular Dystrophy Type 2I in Norway - a Cohort Study

University Hospital of North Norway1 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2020年1月6日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
106
试验地点
1
主要终点
Nocturnal arterial carbon dioxide (CO2)-level

研究概览

简要总结

Key goals are to establish the natural history of limb-girdle muscular dystrophy type 2I (LGMD 2I) and identify feasible and sensitive tools and biomarkers to measure disease affection and progression, determine the Norwegian LGMD 2I prevalence, carrier frequency and genotypes, and to assess health-related quality of life in the Norwegian LGMD 2I population.

Main aims are to facilitate future clinical trials and contribute to good clinical practice with suitable methodology and to complete health and social care in order to optimize the function and quality of daily living of the patient group.

详细描述

A single-center study with Norwegian nationwide enrollment. Data is based on questionnaires, patient journals, clinical examination, a set of functional tests and biomarkers, and patient reported outcomes. Clinical/ paraclinical tests are repeated after 2-years in order to measure disease progression. Both skeletal muscle, heart and respiratory function will be examined. At baseline there will also be performed a sleep study in order to find if they are prone to sleep-disordered breathing.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Genetical confirmed limb-girdle muscular dystrophy type 2I in Norway
  • Live in Norway
  • Written consent

排除标准

  • Children < 16 years are excluded from the assessment of quality of life and from the clinical/paraclinical part, but may contribute with information through questionnaires and patient journal.
  • The study of prevalence and genotypes is anonymous and consent independent and will include everyone that is genetically LGMD 2I-confirmed in Norway.

结局指标

主要结局

Nocturnal arterial carbon dioxide (CO2)-level

时间窗: Baseline

Monitor transcutaneous CO2 during sleep at baseline.

MRI

时间窗: At 2 years

Muscle MRI lower limbs

Echo intensity of muscles

时间窗: Baseline and 2 years

Change in echo intensity at a defined cross-sectional level in muscles in limbs, musculus rectus abdominis and paraspinal muscles from baseline at 2 years. Echo intensity is measured as grayscale pixels ranging from 0 (black) to 255 (white) through histogram analysis by an ultrasound software program. It calculates the mean value from the superficial 1/3 of a manually selected region of interest in three consecutive images from same location. Increase in echo intensity indicates increase in pathology.

Disease-specific health-related quality of life (HRQOL)

时间窗: Baseline, at 6 months, 1 year

Using the "Individualized Neuromuscular Quality of Life" (INQOL)-questionnaire to measure the burden of disease. It consists of 45 items. Each item is graded by a 7-point Likert scale (0-6/1-7).The 45 items make up 3 dimensions/domains: muscular symptoms, effects on life-domains (activities, independence, emotions, body image, social relationships) and effects of treatment. The 3 domains are together subdivided into 11 subdimensions, each with its own subscale. In addition there is a QOL-score which is a composite score from the "Life-domain". The scores range from 0-100 and are determined by the item responses and a weighting algorithm. The higher the scores, the more negative impact. Both subscales and QOL-score will be determined - at baseline and changes from baseline at 6 months, 1 year and 2 years.

Muscle thickness

时间窗: Baseline and 2 years

Using ultrasound to measure changes in muscle thickness at a defined cross-sectional level in muscles in limbs, musculus rectus abdominis and paraspinal muscles from baseline at 2 years.

Age at important disease stages

时间窗: Retrospective data collection at baseline

Document the variation in age of onset, age of loss of walking ability, age of established cardiac failure and age of established respiratory failure.

Rate of symptom progression

时间窗: Retrospective data collection at baseline

Document the variation in time from disease onset to loss of walking ability

Prevalence of initiated ventilation support

时间窗: Retrospective data collection at baseline

The percentage of female and males that have initiated ventilation support.

Prevalence of recognized cardiomyopathy

时间窗: Retrospective data collection at baseline

The percentage of females and males with recognized cardiomyopathy

Motor task performance

时间窗: Baseline and 2 years

Using the standardised scoring instrument "Motor Function Measure for neuromuscular diseases" (MFM) to measure the ability to perform 32 different motor tasks. The individual item score ranges from 0 (cannot initiate the task) to 3 (performs fully and normally). The items are divided into 3 domains: 1) Standing and transfers (13 tasks), 2) Axial and proximal motor function (12 tasks), 3) Distal motor function (7 tasks). The 3 domains give rise to 3 subscores. Both subscores and total score (0-96 points) will be measured. Baseline and changes from baseline at two years.

Echocardiography strain speckle-tracking

时间窗: Baseline and 2 years

Measure cardiac function at baseline and changes from baseline at 2 years

次要结局

  • 4-step stair climb test(Baseline and 2 years)
  • Cough Peak Flow(Baseline and 2 years)
  • Pain (visual analogous scale, VAS)(Baseline and 2 years)
  • Fatigue (Visual Analogous Scale, VAS)(Baseline and 2 years)
  • 6 Minute Walk Test (6MWT)(Baseline (2 tests with 1 day interval) and two years (2 tests with 1 day interval))
  • Hand held dynamometry(Baseline and 2 years)
  • Manual Muscular Testing (MMT)(Baseline and 2 years)
  • General health-related quality of life(Baseline, 6 months, 1 year)
  • Plethysmography(Baseline and 2 years)
  • Diaphragm thickness ratio(Baseline and 2 years)
  • Nocturnal oxygen saturation(Baseline and 2 years)
  • Apnea-hypopnea index(Baseline)
  • Respiratory disturbance index(Baseline)
  • Electrocardiography (ECG)(Baseline and 2 years)
  • Thoracoabdominal breathing pattern during sleep(Baseline)
  • Level of motor independence: "Vignos Grade"(Baseline and 2 years)
  • Echocardiography - conventional(Baseline and 2 years)
  • Capillary blood gas(Baseline and 2 years)
  • Serum Creatine Kinase (s-CK)(Baseline)
  • Upper limb movement ability: "Brooks Grade"(Baseline and 2 years)
  • Mean Inspiratory and Expiratory Pressure (MIP/MEP)(Baseline and 2 years)
  • Forced Vital Capacity (FVC)(Baseline and 2 years)
  • Fatigue Severity Scale (FSS)(Baseline and 2 years)
  • Insomnia(Baseline)
  • Epworth Sleepiness Scale (ESS)(Baseline)
  • Sleep quality(Baseline)
  • Cognitive status(Baseline)

研究者

发起方
University Hospital of North Norway
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Limb-Girdle Muscular Dystrophy Type 2I in Norway | 临床试验